Shares of aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) have received an average recommendation of “Buy” from the nine analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target […]
StockNews.com cut shares of aTyr Pharma (NASDAQ:LIFE – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Saturday. Separately, Zacks Investment Research raised shares of aTyr Pharma from a hold rating to a buy rating and set a $6.75 price target on the stock in a […]
aTyr Pharma (NASDAQ:LIFE – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday. Separately, Zacks Investment Research downgraded shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Friday, March 18th. One equities research […]
aTyr Pharma (NASDAQ:LIFE – Get Rating) announced its earnings results on Monday. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03), MarketWatch Earnings reports. During the same period in the prior year, the business earned ($0.47) earnings per share. NASDAQ:LIFE opened at $4.75 on […]